Malignant neoplasm of bronchus and lung, unspecified. Short description: Mal neo bronch/lung NOS. ICD-9-CM 162.9 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim, however, 162.9 should only be used for claims with a date of service on or before September 30, 2015.
Advanced-stage disease (stages II to IV) was defined by claims indicating lymph node involvement or metastases (ICD-9 codes 196-199.1). The tumor registry stagings of the disease for these patients were clustered into two groupings, stages 0-I …
Billable Medical Code for Malignant Neoplasm of Bronchus and Lung, Unspecified Diagnosis Code for Reimbursement Claim: ICD-9-CM 162.9. Code will be replaced by October 2015 and relabeled as ICD-10-CM 162.9. The Short Description Is: Mal neo bronch/lung NOS. Known As
162.9 is a legacy non-billable code used to specify a medical diagnosis of malignant neoplasm of bronchus and lung, unspecified. This code was replaced on September 30, 2015 by its ICD-10 equivalent. Convert 162.9 to ICD-10 The following crosswalk between ICD-9 to ICD-10 is based based on the General Equivalence Mappings (GEMS) information:
ICD-9-CM Code | Description |
---|---|
492.8 | Other emphysema |
493.22 | Chronic obstructive asthma with acute exacerbation |
496 | Chronic airway obstruction, not elsewhere classified |
518.81 | Acute respiratory failure |
Symptoms include intense coughing, shortness of breath, changes in the voice, pain in the chest, wheezing, snoring, drop in weight, headache, and bone pain.
Metastatic lung cancer is cancer that begins somewhere else in the body and spreads to the lungs. Symptoms include intense coughing, shortness of breath, changes in the voice, pain in the chest, wheezing, snoring, drop in weight, headache, and bone pain.
Squamous cell carcinoma of lung, TNM stage 1. Squamous cell carcinoma of lung, TNM stage 2. Squamous cell carcinoma of lung, TNM stage 3. Squamous cell carcinoma of lung, TNM stage 4. T3: Lung tumor of any size in the main bronchus < 2 cm distal to the carina but without involvement of the carina.
162.9 is a legacy non-billable code used to specify a medical diagnosis of malignant neoplasm of bronchus and lung, unspecified. This code was replaced on September 30, 2015 by its ICD-10 equivalent.
Doctors diagnose lung cancer using a physical exam, imaging, and lab tests. Treatment depends on the type, stage, and how advanced it is. Treatments include surgery, chemotherapy, radiation therapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells.
It is a leading cause of cancer death in men and women in the United States. Cigarette smoking causes most lung cancers. The more cigarettes you smoke per day and the earlier you started smoking, the greater your risk of lung cancer. High levels of pollution, radiation and asbestos exposure may also increase risk.
Cancer of the lung, squamous cell, stage 1. Cancer of the lung, squamous cell, stage 2. Cancer of the lung, squamous cell, stage 3. Cancer of the lung, squamous cell, stage 4. Cancer, lung, non small cell. Eaton-lambert syndrome due to small cell carcinoma of lung. Eaton-lambert syndrome due to small cell lung cancer.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm. Morphology [Histology] Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, ...
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm. Morphology [Histology] Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, ...